

Please join us for a 1-hour
CE Satellite Symposium

GAUCHER DISEASE

Challenges in Assessment and Management of Bone Disease

Wednesday, February 5, 2025
12:15- 13:15 PST in Grand Hall AB

OVERVIEW

Although Gaucher disease (GD) is one of the most widely known of the lysosomal diseases, and treatments are available, there is still so much that needs to be addressed. This satellite session will aim to address the critical gap in diagnosing and managing bone disease in individuals with Gaucher disease, focusing on the challenges and current treatment protocols. Bone disease, though a common and debilitating aspect of GD, often remains underdiagnosed and undertreated, even during enzyme replacement therapy (ERT), due to the focus on other clinical manifestations. The session will raise awareness and promote the need for standardized protocols for monitoring bone involvement, ultimately shifting from a treatment-based approach to a personalized, patient-centered model of care for bone disease in GD.

CE ACCREDITATION



This activity is jointly provided by Postgraduate Institute for Medicine and Saterdalen & Associates, LLC.



CE CREDIT INFORMATION

Full accreditation information, target audience, learning objectives, and instructions to obtain CE credit or a Certificate of Attendance for this activity are available using the QR code above. Faculty disclosures and eligibility to attend this satellite are also available at this link.

GRANT SUPPORT

This activity is supported by an independent educational grant from Takeda Pharmaceuticals, U.S.A., Inc.

FACULTY



Ozlem Goker-Alpan, MD (Chair)
Lysosomal and Rare Disorders
Research & Treatment Center, Inc.
Fairfax, VA, United States



Patrick Deegan, MD
Cambridge University Hospitals
NHS Foundation Trust
Cambridge, UK



Gregory A. Grabowski, MD
Cincinnati Children's Hospital
Research Foundation
Cincinnati, OH, United States



Ravi Kamath, MD, PhD
Fairfax Radiological Consultants
Inova Health System
Fairfax, VA, United States